Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting

Phase 2

Vismodegib, FAK Inhibitor, CapivasertibVismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT02523014

Conditions

Intracranial Meningioma

Recurrent Meningioma

NF2 Gene Mutation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vismodegib

FAK Inhibitor GSK2256098

Capivasertib

Abemaciclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-15. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2026-01-12.